Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04301843 · ClinicalTrials.gov registry record · Phase 2
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
A Phase 2 study of Neuroblastoma, sponsored by Giselle Sholler.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
- 20
- Study locations
NCT04301843 is a Phase 2 study of Neuroblastoma that is actively recruiting participants, run by Giselle Sholler. The registered enrollment target is 131 participants, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT04301843, a Phase 2 study of Neuroblastoma, is actively recruiting participants, sponsored by Giselle Sholler.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
- 20
- Study locations
Study Summary
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.
Conditions Studied
Interventions
- DRUG Eflornithine
Study Locations (20)
California
- UCSF Benioff Children's Hospital Oakland - Oakland
- Rady Children's Hospital - San Diego
Florida
- Arnold Palmer Hospital for Children - Orlando
- St. Joseph's Children's Hospital - Tampa
Missouri
- Children's Mercy Hospitals and Clinics - Kansas City
- Cardinal Glennon Children's Hospital - St Louis
Alabama
- University of Alabama/Children's of Alabama - Birmingham
Arkansas
- Arkansas Children's Hospital - Little Rock
Connecticut
- Connecticut Children's Hospital - Hartford
Georgia
- Augusta University Health - Augusta
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2020-09-25 |
| Est. Completion | 2033-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04301843
The ClinicalTrials.gov registry entry for NCT04301843 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (45% lower). The listed sponsor is Giselle Sholler, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which Eflornithine is the first listed.
NCT04301843 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT04301843 about?
NCT04301843 is a clinical study titled "Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma". Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.
What is the current status of trial NCT04301843?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2020-09-25. Estimated completion is 2033-10-01.
What conditions does trial NCT04301843 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT04301843?
The interventions under investigation include: Eflornithine (DRUG).
Who is sponsoring clinical trial NCT04301843?
This trial is sponsored by Giselle Sholler, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04301843 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
RECRUITING · Phase 2
-
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 2
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
RECRUITING · Phase 2
-
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
RECRUITING · Phase 2
-
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.